KPIs & Operating Metrics(New)
Growth Metrics

Bristol Myers Squibb (BMY) Current Assets (2016 - 2026)

Bristol Myers Squibb has reported Current Assets over the past 18 years, most recently at $27.2 billion for Q1 2026.

  • Quarterly Current Assets fell 11.61% to $27.2 billion in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $27.2 billion through Mar 2026, down 11.61% year-over-year, with the annual reading at $29.4 billion for FY2025, 1.31% down from the prior year.
  • Current Assets was $27.2 billion for Q1 2026 at Bristol Myers Squibb, down from $29.4 billion in the prior quarter.
  • Over five years, Current Assets peaked at $35.6 billion in Q3 2025 and troughed at $26.8 billion in Q3 2022.
  • The 5-year median for Current Assets is $28.7 billion (2024), against an average of $29.3 billion.
  • Year-over-year, Current Assets decreased 18.01% in 2022 and then rose 26.91% in 2025.
  • A 5-year view of Current Assets shows it stood at $27.3 billion in 2022, then rose by 16.49% to $31.8 billion in 2023, then dropped by 6.26% to $29.8 billion in 2024, then fell by 1.31% to $29.4 billion in 2025, then dropped by 7.42% to $27.2 billion in 2026.
  • Per Business Quant, the three most recent readings for BMY's Current Assets are $27.2 billion (Q1 2026), $29.4 billion (Q4 2025), and $35.6 billion (Q3 2025).